COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,891 Articles (22,568 medRxiv, 8,323 bioRxiv)

Most recent first Previous |  Page 1219: Articles 12181-12190  | Next

Computational drug repurposing against SARS-CoV-2 reveals plasma membrane cholesterol depletion as key factor of antiviral drug activity
Barsi, S., Papp, H., Valdeolivas Urbelz, A., Toth, D. J., Kuczmog, A., Madai, M., Hunyady, L., Varnai, P., Saez-Rodriguez, J., Jakab, F., Szalai, B.
10.1101/2021.09.10.459786 — Posted: 2021-09-10
pH-dependent polymorphism of the structure of SARS-CoV-2 nsp7
Lee, Y., Tonelli, M., Rahimi, M., Anderson, T. K., Kirchdoerfer, R. N., Henzler-Wildman, K., Lee, W.
10.1101/2021.09.10.459800 — Posted: 2021-09-10
COVID-19 Vaccine Concerns about Safety, Effectiveness and Policies in the United States, Canada, Sweden, and Italy among Unvaccinated Individuals
Piltch-Loeb, R., Harriman, N., Healey, J., Bonetti, M., Toffolutti, V., Testa, M., Su, M., Savoia, E.
10.1101/2021.09.09.21263328 — Posted: 2021-09-10
Epidemic Models for COVID-19 during the First Wave from February to May 2020: a Methodological Review
Garin, M., Limnios, M., Nicolai, A., Bargiotas, I., Boulant, O., Chick, S. E., Dib, A., Evgeniou, T., Fekom, M., Kalogeratos, A., Labourdette, C., Ovchinnikov, A., Porcher, R., Pouchol, C., Vayatis, N.
10.1101/2021.09.02.21263033 — Posted: 2021-09-10
Exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021
Elliott, P., Haw, D. J., Wang, H., Eales, O., Walters, C. E., Ainslie, K. E. C., Atchison, C. J., Fronterre, C., Diggle, P., Page, A. J., Trotter, A., Prosolek, S. J., The COVID-19 Genomics UK (COG-UK) consortium, , Ashby, D., Donnelly, C., Barclay, W., Taylor, G. P., Cooke, G., Ward, H., Darzi, A., Riley, S.
10.1101/2021.09.02.21262979 — Posted: 2021-09-10 Discussion: Onsite
metaCOVID: An R-Shiny application for living meta-analyses of COVID-19 trials
Evrenoglou, T., Boutron, I., Chaimani, A.
10.1101/2021.09.07.21263207 — Posted: 2021-09-10
Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort
Handy, A., Banerjee, A., Wood, A., Dale, C., Sudlow, C., Tomlinson, C., Bean, D., Thygesen, J. H., Mizani, M. A., Katsoulis, M., Sofat, R., Dobson, R., Takhar, R., Hollings, S., Denaxas, S., Walker, V., CVD-COVID-UK Consortium
10.1101/2021.09.03.21263023 — Posted: 2021-09-10
Induction of trained immunity by influenza vaccination - impact on COVID-19
Debisarun, P. A., Gössling, K. L., Bulut, O., Kilic, G., Zoodsma, M., Liu, Z., Oldenburg, M., Rüchel, N., Zhang, B., Xu, C.-J., Struycken, P., Koeken, V. A. C. M., Dominguez-Andres, J., Moorlag, S. J. C. F. M., Taks, E., Ostermann, P. N., Müller, L., Schaal, H., Adams, O., Borkhardt, A., ten Oever, J., van Crevel, R., Li, Y., Netea, M.
10.1101/2021.09.03.21263028 — Posted: 2021-09-10
Seroprevalence of anti-SARS-CoV-2 IgG and IgA antibodies before the launch of COVID-19 vaccination in Kazakhstan.
Kadyrova, I., Yegorov, S., Negmetzhanov, B., Kolesnikova, Y., Kolesnichenko, S., Korshukov, I., Akhmaltdinova, L., Vazenmiller, D., Turmukhambetova, A., Miller, M. S., Hortelano, G., Babenko, D.
10.1101/2021.09.03.21262885 — Posted: 2021-09-10
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune modifying therapies: a nationwide cohort study in the OpenSAFELY platform
MacKenna, B., Kennedy, N. A., Mehkar, A., Rowan, A., Galloway, J., Mansfield, K. E., Bechman, K., Matthewman, J., Yates, M., Brown, J., Schultze, A., Norton, S., Walker, A. J., Morton, C. E., Harrison, D., Bhaskaran, K., Rentsch, C. T., Williamson, E., Croker, R., Bacon, S., Hickman, G., Ward, T., Davy, S., Green, A., Fisher, L., Hulme, W., Bates, C., Curtis, H. J., Tazare, J., Eggo, R. M., Evans, D., Inglesby, P., Cockburn, J., McDonald, H. I., Tomlinson, L. A., Mathur, R., Wong, A. Y., Forbes, H., Parry, J., Hester, F., Harper, S., Douglas, I. J., Smeeth, L., Lees, C. W., Evans, S. J., Goldacre, B., Smith, C., Langan, S. M.
10.1101/2021.09.03.21262888 — Posted: 2021-09-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).